Unknown PHASE2 INTERVENTIONAL 1-arm NCT04796623

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions HR-positive, HER2-negative Advanced Breast Cancer

Interventions Fulvestrant injection TQB3616 capsules

Updated 5 times since 2021 Last updated: Mar 11, 2021 Started: Feb 4, 2021 Primary completion: Jan 31, 2023 Completion: Jan 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HR-positive, HER2-negative Advanced Breast Cancer, this trial is ongoing. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Apr 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Apr 2021 — Apr 2023 [monthly]

Recruiting PHASE2

First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chongqing, China , Dalian, China , Guangzhou, China , Hangzhou, China , Harbin, China , Lanzhou, China , Nanjing, China , Nanning, China and 5 more locations